Saturday, May 10, 2014 10:50:16 AM
A promising approach is the development of antitumor agents in the form of membrane-active cationic Peptiden1 , 2 Without receptors to bind to target these peptides to cells expose negatively charged lipids on the outside of their plasma membrane and lyse their "victim" within minutes. Our biophysical studies on derivatives of natural Abwehrpeptide3 , 4 have shown that these biologically active molecules between different cell membranes may differ. Thus, antimicrobial peptides could be tailored , the sind5 selectively directed against bacterial membranes , cancer cell- active ingredients are in the process of Development6 . The basis for this is the nature of the surface of mammalian membranes. The outside of eukaryotic plasma membranes typically consist of neutral phospholipids , such as phosphatidylcholine (PC) and sphingomyelin (SM ) together , whereas the negatively charged phospholipid phosphatidylserine ( PS) IST7 found only in the inner part of the plasma membrane . Under certain pathological conditions usually this asymmetry may be lost , causing it to an exposure of this negative charged phospholipid PS on the surface of eg Cancer cells occur kann8 . This makes it a point of positively charged peptides.
One challenge is the exposure of PS on tumor cells detected in a simple experiment , and in vitro ( on living cells in culture) and quantified relative to normal cells. For this study , which is carried out under a FWF project at the Institute of Biophysics and Nanosystems Research , cell lines of prostate cancer, kidney cancer , malignant melanoma, a rhabdomyosarcoma and brain tumor on their PS content in the outer lipid layer of their plasma membrane were examined and with the surface compared to that of normal cells , such as melanocytes and synovial cells .
For visualization of PS exposure, the specific binding of fluorescent-labeled Annexin V in the presence of an elevated concentration of Ca2 + was used in the medium, a standard assay which is used for the routine investigation of cells , through which the pre-programmed cell death ( apoptosis). Using fluorescence microscopy, thus could be shown that different tumor cell lines ( Figure 2) , as well as primary cell cultures reflect the specific PS markers on its exterior , while healthy melanocytes expose no PS .
Quantifying the amount of the exposed PS was conducted by fluorescence spectroscopy by means of labeled AnnexinV FITC cells, wherein an up to 15 -fold increase in PS exposure has been found by the cancer cells.
literature
[1 ] Papo , N., Braunstein , A., Eshhar , Z., and Shai , Y. Suppression of human prostate tumor growth in mice by a cytolytic D-, L -amino Acid Peptide : membrane lysis , Increased necrosis , and inhibition of prostate - specific antigen secretion . Cancer Res 64: 5779-5786 , 2004.
[2 ] Yang , N., Stensen , W., Svendsen , JS, and Rekdal , O. Enhanced antitumor activity and selectivity of lactoferrin -derived peptides . J.Pept.Res , 60 . 187-197 , 2002.
[3 ] Zweytick , D., Pabst, G. , Abuja , PM, Jilek , A. , Blonde Elle , SE, Andra , J., Jerala , R. Monreal , D., Martinez, Baptist , and Lohner , K. Influence of N- acylation of a peptide derived from human lactoferricin on membrane selectivity . Biochim. Biophys.Acta , 1758 : 1426-1435 , 2006.
[4 ] Zweytick , D., Tumer , S., Blonde Elle , SE, and Lohner , K. Membrane curvature stress and antibacterial activity of lactoferricin derivatives . Biochem.Biophys.Res.Commun , 369 . 395-400 , 2008.
[5 ] Lohner , K. and Blonde Elle , SE Molecular mechanisms of membrane perturbation by antimicrobial peptides and the use of biophysical studies in the design of novel peptide antibiotics . . Comb.Chem.High Throughput.Screen , 8 : 241-256 , 2005.
[6 ] Hoskin , DW and Ramamoorthy , A. Studies on anticancer activities of antimicrobial peptides . Biochim.Biophys.Acta , 1778 : 357-375 , 2008.
[7 ] Bevers , EM, Comfurius , P., and Zwaal , RF Regulatory mechanisms in maintenance and modulation of transmembrane lipid asymmetry : pathophysiological implications . Lupus , 5 : 480-487 , 2005.
[8 ] Zwaal , RF and Schroit , AJ pathophysiology implications of membrane phospholipid asymmetry in blood cells . Blood, 89: 1121-1132 , 1997.
Recent CDMO News
- Avid Bioservices Earns Committed Badge from EcoVadis for Sustainability Performance • GlobeNewswire Inc. • 05/23/2024 12:05:46 PM
- Avid Bioservices to Participate at Upcoming Investor Conferences • GlobeNewswire Inc. • 05/07/2024 08:05:11 PM
- Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 04/24/2024 09:25:33 PM
- Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q • GlobeNewswire Inc. • 03/20/2024 11:00:10 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:30:11 AM
- Avid Bioservices Announces Pricing of Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/07/2024 04:58:48 AM
- Avid Bioservices Announces Proposed Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/06/2024 09:32:07 PM
- Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 03/06/2024 09:31:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:30:18 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:57:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2024 12:34:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:39:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:38:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:37:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:36:27 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:35:47 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/11/2024 12:56:02 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/08/2024 09:32:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:56:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:55:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:53:58 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:51:57 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 12/19/2023 09:05:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 12:34:08 AM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM